#SAE@simecatlantis: a quick delve into developments at Uskmouth and the overall power plant conversion division.
Specifically re: Uskmouth, the importance of a particular update in the 16/07/2020 RNS has been overlooked:
"Development of private wire offtake opportunity."
1/14
The house broker's numbers assume a route-to-market private purchase agreement (essentially selling directly to the grid at wholesale prices) for 80% of the 220MW output, with 20% going to a private wire PPA.
The RtM PPA is priced at £45/MWh, whilst the PW PPA is £70/MWh.
2/14
The PW PPA would be with a data centre. There are DCs already in operation a few miles away; and #SAE is also exploring the option of developing DCs on land directly adjacent to Uskmouth.
Industrial customers usually source power directly from the grid at at least £100/MWh 3/14
I believe it's #SAE's intention to put in place PW PPAs with one or more DCs for ALL of Uskmouth's 220MW output.
DCs would be sourcing energy from Uskmouth at say £70/MWh - a 30% discount to what they would usually have to pay.
Uskmouth would be selling at a ~55% premium...4/14
..to what it would normally receive, were it all being fed into the grid. A win-win.
House broker Arden's revenue forecast for Uskmouth in 2025 (assuming 2% inflation pa) is £103m (including ROCS - the government support mechanism - of £21.5m).
Its EBITDA forecast is £70m. 5/14
If we assume ALL 220MW of output went via PW PPA to DCs, revenue (including ROCS) would increase to £136m.
This would essentially fall right down to EBITDA - which would translate into 2025 EBITDA of just over £100m.
I expect we'll hear of a PW PPA in the next 8 weeks.
6/14
The second point relates to the new fuel JV with N+P. This is a historic development for #SAE, second in importance only to 23/06/20 RNS (success in large scale combustion testing of fuel).
Firstly, with regards to Uskmouth:
The JV (50% owned by SAE, 50% by N+P) will be... 7/14
...constructing 4 fuel processing plants across the UK. Capex for each plant will be ~£30m (based on the cost of the first UK plant already constructed by N+P).
Each plant will produce 220 thousand tonnes pa of fuel (Uskmouth at full output will require 880ktpa of fuel).
8/14
It requires 1t of waste (50% plastic, 50% paper / cardboard) to produce 0.75t of fuel pellets. Thus each 220ktpa processing plant will require ~293ktpa of waste input.
Landfill currently costs circa £100/t. As such, were #SAE's processing plants to charge say £70/t to... 9/14
receive waste from waste management companies, those companies would be making a 30% saving.
70 x 293,000 = £20.5m
#SAE's JV will then be selling the fuel plants directly to Uskmouth at say £6/t.
6 x 220,000 = £1.3m
Total revenue per 220ktpa plant: £21.8m
Margins?
10/14
Assuming an EBITDA margin of 40-50%, that's £8.7m to £10.9m.
4 plants equates to revs of ~£87m, EBITDA of ~£40m.
#SAE's share will be 50% - so an extra £20m EBITDA for the Uskmouth project.
In total then, assuming PW PPAs are agreed with new DCs for the full 220MW, then..11/14
#SAE's share of the EBITDA generated by the overall Uskmouth project could be £120m to £125m by 2025.
This is what I think the wider market is missing.
Beyond Uskmouth however, the upside is almost unquantifiable. It has the knowhow for coal plant conversions - there are..12/14
almost 2,500 plants in operation worldwide. And via the new JV, #SAE now has a proprietary fuel that it is itself going to be manufacturing.
The fuel's emissions are ~60% less than coal - and it also rids the world of vast amounts of non-recyclable plastic waste.
13/14
I expect there to be a global rollout of #SAE's integrated tech (waste purchase all the way through to energy generation) in the coming years.
The big question is, will it build a huge proprietary estate of plants (the ultimate goal), or focus on provision of services? 14/14
• • •
Missing some Tweet in this thread? You can try to
force a refresh
There are many stale holders who have been underwater for 18+ months, who will be happy to take some cash out now, in this ongoing cost of living crisis. That is understandable.
There will also be traders exiting, having positioned for this update.
Furthermore, the...
2/20
...wider investment community has not yet heard of, and even more so not appreciated the significance of, today's news at #AVCT.
Finally, I will state with a high degree of confidence that today's RNS opens the floodgates for numerous more updates in the near future.
Volume returning really nicely to the small cap space, which is creating excellent trading conditions.
My average holding period in the Short-term Trading Portfolio is still around 16 sessions / 3 weeks.
Seemingly contrary to many, I consider trade entries based both on..
2/18
...fundamentals (see two recent successful trades in MMAG and SPEC, with rationales for trades founded on earnings metrics), and on stories and associated sentiment (BSFA being most recent example).
I don't subscribe to only utilizing one or the other; the same way as I...
@AnEarlofWisdom Hi Earl, I can't see any of the posts, as I'm blocked by those accounts (or I've blocked!), but I've been told there's a lot of scaremongering about various things:
1) Delay in trial; 2) Dox not activating much in TME; 3) Low cash balance, and thus possible placing coming.
1/8
@AnEarlofWisdom On the contrary, except for Cohorts 1 and 2 taking longer than expected (due to patient withdrawals - nothing whatsoever to do with #AVA6000 itself), #AVCT's progress in 2022 could not be stronger.
The DE to 200mg/m2 was the ultimate target, so that nullifies point 2) ⬆️.
2/8
@AnEarlofWisdom Licensing deals for targeted oncology drugs - even those at pre-clinical stage, like 3996 - have been monstrous in recent times (e.g. $100m cash upfront for an antibody-drug conjugate, just last month ⬇️).
...substrate to FAP is so high that the concentration ratio of active doxorubicin in the tumour : healthy tissue, will negate the requirement for increase in dose size. [My view!]
Enough dox is already becoming active in the tumour micro-environment, at the current...
3/8
$SGEN specializes in antibody-drug conjugates ('ADC') - a relatively novel form of targeted cancer treatment.
@avacta's targeted cancer treatment platform, preCISION, has the real potential of generating pro-chemotherapies that are MORE targeted than ADCs, and thus...
2/6
...also potentially capable of delivering a more potent drug payload.
#AVCT will be announcing the results of the first preCISION prodrug P1 trial (AVA6000) in the next few months.
Success will mean the platform could be used to modify many other existing chemotherapies.
3/6